ABECMA (idecabtagene vicleucel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

This website is best viewed using the horizontal display on your tablet device.

This website is best viewed using the vertical display on your mobile device.

ABECMA® Is a Personalized Immune Cell Therapy That Targets BCMA With a One-Time Infusion1*

MOA Video Thumbnail

Watch MOA video

Antigen-specific activation of ABECMA results in CAR-positive T cell proliferation, cytokine secretion, and subsequent cytolytic killing of BCMA-expressing cells.1

ABECMA® CAR T Cell Diagram

ABECMA consists of T cells reengineered to express a CAR that contains:

ABECMA® CAR T Cell Diagram
  • 1An extracellular scFv-targeting domain that binds specifically to BCMA, a cell-surface antigen expressed at significantly higher levels on malignant plasma cells of MM1,2
  • 2A CD8α hinge that provides stability for CAR T cell expression and flexibility to access the targeted antigen1,3
  • 3A 4-1BB costimulatory domain, which is associated with enhanced CAR T cell activation, expansion, and persistence1,4
  • 4A CD3ζ signaling domain, which leads to CAR-positive T cell activation in response to binding of BCMA-expressing target cells1

BCMA is expressed both on normal and malignant plasma cells.



BCMA expression is largely restricted to plasma cells and is uniquely overexpressed on myeloma cells, making BCMA a promising target antigen.1,2

Learn more about ABECMA®
efficacy & safety

Find a certified
treatment center near you

Treatment process includes leukapheresis, manufacturing, administration, and adverse event monitoring. A single dose of ABECMA contains a cell suspension of 300 to 460 x 106 CAR-positive T cells in one or more infusion bags.

BCMA=B-cell maturation antigen; CAR=chimeric antigen receptor; MM=multiple myeloma; MOA=mechanism of action; RRMM=relapsed/refractory multiple myeloma; scFv=single-chain variable fragment.